AC Immune (ACIU) Competitors $2.13 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.10 -0.03 (-1.64%) As of 08/15/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. MLYS, IMNM, ZYME, ATAI, URGN, OCS, ORIC, NUVB, SION, and NAGEShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Mineralys Therapeutics (MLYS), Immunome (IMNM), Zymeworks (ZYME), atai Life Sciences (ATAI), Urogen Pharma (URGN), Oculis (OCS), Oric Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Sionna Therapeutics (SION), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors Mineralys Therapeutics Immunome Zymeworks atai Life Sciences Urogen Pharma Oculis Oric Pharmaceuticals Nuvation Bio Sionna Therapeutics Niagen Bioscience AC Immune (NASDAQ:ACIU) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Do analysts rate ACIU or MLYS? AC Immune currently has a consensus price target of $12.00, indicating a potential upside of 463.38%. Mineralys Therapeutics has a consensus price target of $32.25, indicating a potential upside of 122.11%. Given AC Immune's stronger consensus rating and higher possible upside, research analysts clearly believe AC Immune is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor ACIU or MLYS? In the previous week, Mineralys Therapeutics had 16 more articles in the media than AC Immune. MarketBeat recorded 19 mentions for Mineralys Therapeutics and 3 mentions for AC Immune. Mineralys Therapeutics' average media sentiment score of 0.94 beat AC Immune's score of 0.67 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AC Immune Positive Mineralys Therapeutics Positive Which has more risk and volatility, ACIU or MLYS? AC Immune has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Do institutionals and insiders believe in ACIU or MLYS? 51.4% of AC Immune shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, ACIU or MLYS? AC Immune has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$28.92M7.40-$57.83M-$0.58-3.67Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-4.08 Is ACIU or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -174.94%. AC Immune's return on equity of -49.35% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AC Immune-174.94% -49.35% -23.16% Mineralys Therapeutics N/A -70.44%-65.51% SummaryAC Immune beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.87M$3.09B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-3.6720.3830.5825.14Price / Sales7.40364.30465.48115.90Price / CashN/A42.3037.4059.05Price / Book2.378.659.096.18Net Income-$57.83M-$54.65M$3.25B$265.02M7 Day Performance-0.47%6.58%7.34%4.21%1 Month Performance3.40%7.54%5.44%2.02%1 Year Performance-36.80%13.73%30.64%24.21% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune1.8311 of 5 stars$2.13flat$12.00+463.4%-37.2%$213.87M$28.92M-3.67140MLYSMineralys Therapeutics3.2169 of 5 stars$13.19+1.5%$32.25+144.5%+48.8%$847.28MN/A-3.5428News CoverageEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionIMNMImmunome1.8248 of 5 stars$9.66-0.3%$23.14+139.6%-26.3%$843.47M$9.04M-3.1440ZYMEZymeworks0.1153 of 5 stars$12.44+3.5%N/AN/A$837.60M$76.30M-12.82460ATAIatai Life Sciences3.0287 of 5 stars$3.96-4.1%$11.25+184.1%+210.4%$827.39M$310K-4.3580News CoverageEarnings ReportURGNUrogen Pharma4.6248 of 5 stars$18.24+2.8%$31.43+72.3%+27.2%$820.96M$90.40M-5.49200Insider TradeAnalyst RevisionOCSOculis3.0846 of 5 stars$17.97-1.3%$35.33+96.6%+50.4%$795.09M$780K-6.812Short Interest ↓ORICOric Pharmaceuticals4.7245 of 5 stars$9.20-0.4%$18.57+101.9%-10.8%$787.47MN/A-4.9280News CoverageEarnings ReportAnalyst UpgradeShort Interest ↓Analyst RevisionNUVBNuvation Bio2.3503 of 5 stars$2.24-2.8%$7.33+228.1%+0.0%$782.60M$7.87M-3.5560Gap UpSIONSionna Therapeutics2.129 of 5 stars$20.03+13.4%$38.50+92.2%N/A$779.68MN/A0.0035Positive NewsEarnings ReportAnalyst UpgradeGap UpNAGENiagen Bioscience1.363 of 5 stars$9.82+0.9%$13.42+36.7%N/A$776M$99.60M46.76120News CoverageAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Immunome Competitors Zymeworks Competitors atai Life Sciences Competitors Urogen Pharma Competitors Oculis Competitors Oric Pharmaceuticals Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Niagen Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access